Have a feature idea you'd love to see implemented?
Let us know!
IBIO iBio Inc
Price (delayed)
$2.78
Market cap
$24.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.5
Enterprise value
$14.41M
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and
Highlights
IBIO's debt has plunged by 73% from the previous quarter and by 72% YoY
The EPS has soared by 94% YoY but it has contracted by 31% from the previous quarter
The company's net income has surged by 62% YoY but it fell by 8% QoQ
Key stats
What are the main financial stats of IBIO
Market
Valuations
Earnings
Shares outstanding
8.64M
Market cap
$24.01M
Enterprise value
$14.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.12
Price to sales (P/S)
47.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.05
Revenue
$225,000
EBIT
-$24.74M
EBITDA
-$23.49M
Free cash flow
-$17.65M
Per share
Balance sheet
Liquidity
EPS
-$6.5
Free cash flow per share
-$4.61
Book value per share
$2.47
Revenue per share
$0.06
TBVPS
$6.1
Total assets
$28.73M
Total liabilities
$7.41M
Debt
$4.82M
Equity
$21.32M
Working capital
$11.83M
Debt to equity
0.23
Current ratio
4.08
Quick ratio
3.94
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
-10,437.8%
Gross margin
100%
Net margin
-11,069.8%
Operating margin
-7,392.9%
Return on assets
-66.2%
Return on equity
-145.2%
Return on invested capital
-111.3%
Return on capital employed
-99.4%
Return on sales
-10,993.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBIO stock price
How has the iBio stock price performed over time
Intraday
-3.81%
1 week
-2.46%
1 month
50.27%
1 year
-53.9%
YTD
102.92%
QTD
25.23%
Financial performance
How have iBio's revenue and profit performed over time
Revenue
$225,000
Gross profit
$225,000
Operating income
-$16.63M
Net income
-$24.91M
Gross margin
100%
Net margin
-11,069.8%
The company's operating margin has surged by 80% QoQ
IBIO's net margin has soared by 76% from the previous quarter
The company's net income has surged by 62% YoY but it fell by 8% QoQ
The operating income has increased by 43% year-on-year and by 9% since the previous quarter
Growth
What is iBio's growth rate over time
Valuation
What is iBio stock price valuation
P/E
N/A
P/B
1.12
P/S
47.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.05
The EPS has soared by 94% YoY but it has contracted by 31% from the previous quarter
IBIO's price to book (P/B) is 95% higher than its last 4 quarters average of 0.6 but 55% lower than its 5-year quarterly average of 2.6
The company's equity rose by 39% YoY but it fell by 14% QoQ
IBIO's price to sales (P/S) is 63% less than its last 4 quarters average of 133.4 and 43% less than its 5-year quarterly average of 86.7
Efficiency
How efficient is iBio business performance
The ROS has soared by 76% from the previous quarter
iBio's return on assets has increased by 44% YoY but it has decreased by 17% QoQ
iBio's return on equity has increased by 44% YoY
The ROIC has grown by 39% YoY but it has contracted by 24% from the previous quarter
Dividends
What is IBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBIO.
Financial health
How did iBio financials performed over time
IBIO's current ratio has surged by 141% since the previous quarter
The company's total liabilities has shrunk by 71% YoY and by 71% QoQ
IBIO's debt is 77% less than its equity
The company's debt to equity has shrunk by 80% YoY and by 68% QoQ
IBIO's debt has plunged by 73% from the previous quarter and by 72% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.